Zura Bio Limited Class A (ZURA)
NASDAQ: ZURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZURA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $89.63M
- EPS (TTM)
- -$1.11
- Dividend yield
- None
- 52-week range
- 0.919 – 7.44
- Day range
- 0.9192 – 1.00
- Volume / Avg
- 4.76M / 4.47M
- Beta
- —
- Shares outstanding
- 96.33M
52-week range
ZURA stock today
Shares of Zura Bio (ZURA) finished lower on Nov 20 at $0.9305, a drop of 2.30% or $0.0219 per share, versus the S&P 500's 3.70% decline. At this level, ZURA sits near the bottom of its 52-week range of $0.919 to $7.44: 87.5% below the high, set on Mar 10, 2026 and 1.3% above the low. ZURA is down 82.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 74.4%.
Zura Bio has posted a net loss over the last twelve months (EPS of -$1.11), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Zura Bio
Company profileZura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Sandeep Chidambar Kulkarni M.D.
- Headquarters
- Henderson, NV
- Employees
- 40
- Website
- zurabio.com
Financial highlights
Full financialsZura Bio reported a net loss of $68.7 million, compared with a loss of $52.4 million a year earlier. Diluted earnings per share came in at -$1.06.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-68.65M | $-52.40M | $-60.36M | $-25.70M |
| EPS (diluted) | $-1.06 | $-0.60 | $-2.09 | — |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$8.00+759.75%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.20 vs $-0.22
- Surprise
- +9.09%
ZURA news
All ZURA newsZura Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs ZURA |
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs ZURA |
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs ZURA |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs ZURA |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs ZURA |
| BDTXBlack Diamond Therapeutics Inc. | 1.31 | -5.76% | $75.28M | vs ZURA |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs ZURA |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs ZURA |
Indexes, lists and sector
Zura Bio stock FAQ
What is Zura Bio's stock price today?
ZURA last traded at $0.9305 as of Nov 20, 4:00 PM EST, down 2.30% on the day. Prices are delayed at least 15 minutes.
Who is Zura Bio's CEO?
Dr. Sandeep Chidambar Kulkarni M.D. is the chief executive officer of Zura Bio Limited Class A, which has about 40 employees.
What is the ZURA 52-week high?
The 52-week high for ZURA is $7.44 and the 52-week low is $0.919. The stock is currently 87.5% below its high.